MATTHEW RAND: Open Payments
NPI 1427670520 · PORT ANGELES, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,127 in 52 payments from 10 companies in 2025. Trend: 2023 $481 · 2024 $1,402 · 2025 $1,127
Food & beverage: $1,127
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 20 | $525 |
| Novartis Pharmaceuticals Corporation | 13 | $191 |
| ABBVIE INC. | 8 | $144 |
| UCB, Inc. | 3 | $82 |
| Organon LLC | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Lilly USA, LLC | 1 | $33 |
| GENZYME CORPORATION | 1 | $32 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| Amgen Inc. | 1 | $18 |
Products named: TREMFYA, COSENTYX, SKYRIZI, Bimzelx, DUPIXENT, TALTZ, RINVOQ, Sotyktu.
Industry payments across WA — which companies pay providers there.
